Teva Announces Launch of Generic Gleevec(R) Tablets in the United States

JERUSALEM--(Healthcare Sales & Marketing Network)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the launch of the generic equivalent to Gleevec®1(imatinib mesylate) tablets,100 mg and 400 mg, in the United States for multip... Biopharmaceuticals, Generics, Oncology, Product Launch Teva Pharmaceutical, Gleevec, imatinib
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news